CLOSEOUT LETTER
Warrender Enterprise Inc. d/b/a Lifted Liquids and E-Liquid Retail MARCS-CMS 553196 —
- Recipient:
- Warrender Enterprise Inc. d/b/a Lifted Liquids and E-Liquid Retail
United States
- Issuing Office:
United States
|
|
|
|
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993
|
July 31, 2018
VIA UPS and Electronic Mail
Nicholas S. Warrender
Warrender Enterprise Inc.
d/b/a Lifted Liquids and E-Liquid Retail
12715 210th Avenue
Bristol, WI 53104
info@liftedliquids.com
RE: Warning Letter issued to Warrender Enterprise Inc. d/b/a Lifted Liquids and E-Liquid Retail (RW1800864)
Dear Nicholas S. Warrender:
On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Vape Heads Sour Smurf Sauce e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Vape Heads Sour Smurf Sauce e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children.
On May 2, 2018, June 14, 2018, July 12, 2018, and July 19, 2018, you sent FDA a response to the Warning Letter, and we held teleconferences on June 13, 2018 and July 19, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violation identified in the Warning Letter.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.
Sincerely,
/S/
/S/
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
VIA UPS and Electronic Mail
cc:
H. Scott Hecker
Law Offices of H. Scott Hecker, P.A.
400 Southeast Ninth Street
Fort Lauderdale, FL 33316
heckerlawfirm@gmail.com
Nicholas Warrender
liftedbusiness@gmail.com
Network Solutions, LLC
abuse@web.com
GoDaddy.com, LLC
abuse@godaddy.com
Amazon Technologies Inc.
abuse@amazonaws.com
Shopify, Inc.
abuse@shopify.com